JP2015503505A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015503505A5 JP2015503505A5 JP2014548902A JP2014548902A JP2015503505A5 JP 2015503505 A5 JP2015503505 A5 JP 2015503505A5 JP 2014548902 A JP2014548902 A JP 2014548902A JP 2014548902 A JP2014548902 A JP 2014548902A JP 2015503505 A5 JP2015503505 A5 JP 2015503505A5
- Authority
- JP
- Japan
- Prior art keywords
- nitrogen
- optionally substituted
- membered
- pharmaceutically acceptable
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 246
- 229910052757 nitrogen Inorganic materials 0.000 claims description 157
- 229910052760 oxygen Inorganic materials 0.000 claims description 129
- 229910052717 sulfur Chemical group 0.000 claims description 128
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 123
- 125000005842 heteroatom Chemical group 0.000 claims description 123
- 239000001301 oxygen Chemical group 0.000 claims description 123
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 122
- 239000011593 sulfur Chemical group 0.000 claims description 122
- 229910052739 hydrogen Inorganic materials 0.000 claims description 87
- 239000001257 hydrogen Substances 0.000 claims description 87
- 150000001875 compounds Chemical class 0.000 claims description 86
- 125000000623 heterocyclic group Chemical group 0.000 claims description 71
- 125000001931 aliphatic group Chemical group 0.000 claims description 70
- 125000002723 alicyclic group Chemical group 0.000 claims description 62
- 150000003839 salts Chemical class 0.000 claims description 61
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 59
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 52
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 48
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 46
- 150000002431 hydrogen Chemical class 0.000 claims description 34
- 125000002947 alkylene group Chemical group 0.000 claims description 22
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 20
- 229910052799 carbon Inorganic materials 0.000 claims description 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 150000002367 halogens Chemical class 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 125000004429 atom Chemical group 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 2
- 208000006029 Cardiomegaly Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 101000605630 Homo sapiens Phosphatidylinositol 3-kinase catalytic subunit type 3 Proteins 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 108091007960 PI3Ks Proteins 0.000 claims description 2
- 102100038329 Phosphatidylinositol 3-kinase catalytic subunit type 3 Human genes 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000038016 acute inflammation Diseases 0.000 claims description 2
- 230000006022 acute inflammation Effects 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 230000036783 anaphylactic response Effects 0.000 claims description 2
- 208000003455 anaphylaxis Diseases 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 230000006020 chronic inflammation Effects 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- 241001228709 Suruga Species 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000000034 method Methods 0.000 description 5
- 0 *c1c(*)nc(*)[n]1* Chemical compound *c1c(*)nc(*)[n]1* 0.000 description 2
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical group [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- -1 2-chloro-6-fluorophenyl Chemical group 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161579711P | 2011-12-23 | 2011-12-23 | |
| US61/579,711 | 2011-12-23 | ||
| US201261672030P | 2012-07-16 | 2012-07-16 | |
| US61/672,030 | 2012-07-16 | ||
| US201261716172P | 2012-10-19 | 2012-10-19 | |
| US61/716,172 | 2012-10-19 | ||
| PCT/US2012/070988 WO2013096642A1 (en) | 2011-12-23 | 2012-12-20 | Heteroaryls and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015503505A JP2015503505A (ja) | 2015-02-02 |
| JP2015503505A5 true JP2015503505A5 (enExample) | 2016-02-18 |
Family
ID=48655164
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014548896A Pending JP2015503504A (ja) | 2011-12-23 | 2012-12-20 | ヘテロアリールおよびその使用 |
| JP2014548899A Pending JP2015506347A (ja) | 2011-12-23 | 2012-12-20 | ヘテロアリールおよびその使用 |
| JP2014548902A Pending JP2015503505A (ja) | 2011-12-23 | 2012-12-20 | ヘテロアリールおよびその使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014548896A Pending JP2015503504A (ja) | 2011-12-23 | 2012-12-20 | ヘテロアリールおよびその使用 |
| JP2014548899A Pending JP2015506347A (ja) | 2011-12-23 | 2012-12-20 | ヘテロアリールおよびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20130165483A1 (enExample) |
| EP (3) | EP2793880A4 (enExample) |
| JP (3) | JP2015503504A (enExample) |
| AR (3) | AR089446A1 (enExample) |
| TW (3) | TW201331194A (enExample) |
| UY (3) | UY34539A (enExample) |
| WO (3) | WO2013096642A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009094224A1 (en) | 2008-01-25 | 2009-07-30 | Millennium Pharmaceuticals, Inc. | Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
| US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
| JP2012516329A (ja) | 2009-01-30 | 2012-07-19 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Ｐｉ３ｋ阻害剤としてのヘテロアリールおよびその使用 |
| EP2603214A4 (en) | 2010-08-11 | 2013-12-18 | Millennium Pharm Inc | HETEROARYLE AND USES THEREOF |
| US8859768B2 (en) | 2010-08-11 | 2014-10-14 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| US9062038B2 (en) | 2010-08-11 | 2015-06-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| MX2013004003A (es) | 2010-10-13 | 2013-10-01 | Millenium Pharmaceuticals Inc | Heteroarilos y usos de los mismos. |
| CR20160136A (es) | 2013-08-28 | 2016-08-04 | Medivation Technologies Inc | Compuestos heterocíclicos |
| TN2016000270A1 (en) | 2014-01-14 | 2017-10-06 | Millennium Pharm Inc | Heteroaryls and uses thereof. |
| WO2015108881A1 (en) | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| WO2016050921A1 (en) * | 2014-10-02 | 2016-04-07 | F. Hoffmann-La Roche Ag | Pyrazole carboxamide compounds for use in the treament of disorders mediated by bruton's tyrosine kinase (btk) |
| EP3265088A1 (en) | 2015-03-04 | 2018-01-10 | Medivation Technologies LLC | Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance |
| EP3265457A1 (en) | 2015-03-04 | 2018-01-10 | Medivation Technologies LLC | Sterol regulatory element-binding proteins (srebps) inhibitors |
| TW201808906A (zh) | 2016-03-16 | 2018-03-16 | 拜耳作物科學股份有限公司 | 作為殺蟲劑之經取代吡啶化合物 |
| EP3284739A1 (de) | 2017-07-19 | 2018-02-21 | Bayer CropScience Aktiengesellschaft | Substituierte (het)arylverbindungen als schädlingsbekämpfungsmittel |
| ES2962961T3 (es) | 2017-07-28 | 2024-03-22 | Yuhan Corp | Procedimiento de preparación de n-(5-((4-(4-(dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoxi-2-morfolinofenil)acrilamida haciendo reaccionar la amina correspondiente con un cloruro de 3-halo-propionilo |
| DK3658547T3 (da) * | 2017-07-28 | 2023-10-16 | Yuhan Corp | Fremgangsmåde til fremstilling af n-(5-(4-(4-formyl-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamid |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CN110041252A (zh) * | 2019-05-22 | 2019-07-23 | 南京合巨药业有限公司 | 一种2-氯-4-肼基吡啶的制备方法 |
| JP2022535228A (ja) * | 2019-05-31 | 2022-08-05 | バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニー | チアゾリルピラゾールカルボン酸の製造方法およびそれらのための中間体 |
| WO2021011723A1 (en) * | 2019-07-18 | 2021-01-21 | Avidence Therapeutics, Inc. | Anti-osteoarthritis hydantoin compounds and related compositions and methods |
| EP4284804A1 (en) | 2021-01-26 | 2023-12-06 | Schrödinger, Inc. | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders |
| AU2024389419A1 (en) * | 2023-11-27 | 2026-06-11 | Rubedo Life Sciences, Inc. | Carbon linked bcl inhibitors and senolytic compounds and uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH27357A (en) * | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
| IL104369A0 (en) * | 1992-01-13 | 1993-05-13 | Smithkline Beecham Corp | Novel compounds and compositions |
| GB2306108A (en) * | 1995-10-13 | 1997-04-30 | Merck & Co Inc | Treatment of Raf-mediated cancers with imidazole derivatives |
| IL136768A0 (en) * | 1997-12-22 | 2001-06-14 | Bayer Ag | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS |
| JP4316893B2 (ja) * | 2001-05-16 | 2009-08-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｓｒｃおよび他のプロテインキナーゼのインヒビター |
| CA2455181C (en) * | 2001-08-01 | 2010-04-06 | Merck & Co., Inc. | Benzimidazo[4,5-f]isoquinolinone derivatives |
| US7582631B2 (en) * | 2004-01-14 | 2009-09-01 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| AU2005319455A1 (en) * | 2004-12-21 | 2006-06-29 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
| EP1845973B1 (en) * | 2005-01-21 | 2015-08-12 | Astex Therapeutics Limited | Pharmaceutical compounds |
| BRPI0713187A2 (pt) * | 2006-07-20 | 2012-10-16 | Mehmet Kahraman | método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica |
| UY30892A1 (es) * | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| JP2010522770A (ja) * | 2007-03-29 | 2010-07-08 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ａｋｔ活性の阻害物質 |
| GB0709031D0 (en) * | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| US7928140B2 (en) * | 2007-08-02 | 2011-04-19 | Amgen Inc. | Benzothiazole PI3 kinase modulators for cancer treatment |
| WO2009115572A2 (en) * | 2008-03-21 | 2009-09-24 | Novartis Ag | Novel heterocyclic compounds and uses therof |
| CN102066365A (zh) * | 2008-06-19 | 2011-05-18 | 米伦纽姆医药公司 | 噻吩或噻唑衍生物和其作为pi3k抑制剂的用途 |
| WO2009156484A2 (en) * | 2008-06-27 | 2009-12-30 | Novartis Ag | Organic compounds |
| JP2012516329A (ja) * | 2009-01-30 | 2012-07-19 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Ｐｉ３ｋ阻害剤としてのヘテロアリールおよびその使用 |
| WO2010127152A2 (en) * | 2009-04-29 | 2010-11-04 | Irm Llc | Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors |
| CA2760778A1 (en) * | 2009-05-13 | 2010-11-18 | Amgen Inc. | Heteroaryl compounds as pikk inhibitors |
| JO3002B1 (ar) * | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
| EP2627650A2 (en) * | 2010-05-26 | 2013-08-21 | Merck Sharp & Dohme Corp. | N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 |
| WO2012084678A1 (en) * | 2010-12-23 | 2012-06-28 | Syngenta Participations Ag | Novel imidazoles useful as plant fungicides |
| KR20140032383A (ko) * | 2011-03-21 | 2014-03-14 | 에프. 호프만-라 로슈 아게 | Pi3k p110 델타에 대하여 선택적인 벤즈옥사제핀 화합물 및 이의 사용 방법 |
| WO2013093484A1 (en) * | 2011-12-21 | 2013-06-27 | Ono Pharmaceutical Co., Ltd. | Pyridinone and pyrimidinone derivatives as factor xia inhibitors |
-
2012
- 2012-12-20 TW TW101148828A patent/TW201331194A/zh unknown
- 2012-12-20 TW TW101148909A patent/TW201332989A/zh unknown
- 2012-12-20 EP EP12860844.5A patent/EP2793880A4/en not_active Withdrawn
- 2012-12-20 JP JP2014548896A patent/JP2015503504A/ja active Pending
- 2012-12-20 US US13/722,222 patent/US20130165483A1/en not_active Abandoned
- 2012-12-20 US US13/722,134 patent/US20130165464A1/en not_active Abandoned
- 2012-12-20 JP JP2014548899A patent/JP2015506347A/ja active Pending
- 2012-12-20 UY UY0001034539A patent/UY34539A/es not_active Application Discontinuation
- 2012-12-20 US US13/721,877 patent/US20130165472A1/en not_active Abandoned
- 2012-12-20 WO PCT/US2012/070988 patent/WO2013096642A1/en not_active Ceased
- 2012-12-20 UY UY0001034538A patent/UY34538A/es not_active Application Discontinuation
- 2012-12-20 TW TW101148830A patent/TW201332988A/zh unknown
- 2012-12-20 UY UY0001034540A patent/UY34540A/es not_active Application Discontinuation
- 2012-12-20 JP JP2014548902A patent/JP2015503505A/ja active Pending
- 2012-12-20 WO PCT/US2012/070980 patent/WO2013096637A1/en not_active Ceased
- 2012-12-20 EP EP12859082.5A patent/EP2793894A4/en not_active Withdrawn
- 2012-12-20 EP EP12859324.1A patent/EP2793879A4/en not_active Withdrawn
- 2012-12-20 WO PCT/US2012/070969 patent/WO2013096630A1/en not_active Ceased
- 2012-12-26 AR ARP120104957A patent/AR089446A1/es unknown
- 2012-12-26 AR ARP120104956A patent/AR089445A1/es unknown
- 2012-12-26 AR ARP120104958A patent/AR089447A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015503504A5 (enExample) | ||
| JP2015506347A5 (enExample) | ||
| JP6409004B2 (ja) | ソルチリン阻害剤としてのｎ置換された５置換フタルアミド酸 | |
| JP7104999B2 (ja) | インターフェロン遺伝子刺激因子ｓｔｉｎｇのアゴニスト | |
| JP2013533318A5 (enExample) | ||
| JP2020158523A (ja) | 新規ヒストンデアセチラーゼインヒビター | |
| CN105175284B (zh) | 酰胺类化合物、制备方法及其医药用途 | |
| JP2010509231A5 (enExample) | ||
| JP2004509117A5 (enExample) | ||
| JP2006508970A5 (enExample) | ||
| KR20070115879A (ko) | 의학 장애의 치료용 ｃｘｃｒ4 길항제 | |
| JP2019529444A5 (enExample) | ||
| JP2013542941A5 (enExample) | ||
| JP2022105013A (ja) | ケモカインの生物活性を中和するためのピリミジノン誘導体およびその使用 | |
| Carceller et al. | Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity | |
| JP2016508152A (ja) | Ｃｒａｃチャネル阻害薬としての、ピラゾリルをベースとするカルボキサミド類ｉ | |
| CN106243047B (zh) | 具有VEGFR-2和B-raf双重抑制作用的喹喔啉酮双芳基脲及其衍生物、制备方法及其应用 | |
| CN104334528A (zh) | (2-杂芳基氨基)琥珀酸衍生物 | |
| CN112390782B (zh) | 一种特异性增强TRPV4-KCa2.3复合体的空间耦联度的化合物及其用途 | |
| JP2016504397A (ja) | Ｃｒａｃチャネル阻害薬としての、ピラゾリルをベースとするカルボキサミド類ｉｉ | |
| WO2019029295A1 (zh) | 基于帕唑帕尼结构的hdac和vegfr双靶点抑制剂及其制备方法和应用 | |
| JP2018538352A (ja) | Ｃｆｔｒ制御因子及びこの使用方法 | |
| CN103755695B (zh) | 一种具有抗肿瘤活性的酰胺类化合物及其应用 | |
| JP6464244B2 (ja) | Ｔｅｒｔ−ブチル ｎ−［２−｛４−［６−アミノ−５−（２，４−ジフルオロベンゾイル）−２−オキソピリジン−１（２ｈ）−イル］−３，５−ジフルオロフェニル｝エチル）−ｌ−アラニネート又はその製薬上許容され得る塩、水和物もしくは溶媒和物 | |
| KR102821711B1 (ko) | 인터페론 유전자의 자극인자 sting의 비시클릭 효능제 |